Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Blake Peterson

Orthopaedic Surgery Arlington, VA Medical Doctor

NPI 1023379849 CMS profile 182342

2445 Army Navy Dr, Arlington, VA 22206

Open in the dashboard

General payments

$381,753

538 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$147,076 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Blake Peterson of Arlington, VA is reported in the CMS Open Payments database as having received $381,753 across 538 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $147,076 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $183,549 164
2024 General $33,665 51
2023 General $52,234 96
2022 General $38,561 77
2021 General $26,267 58
2020 General $39,124 50
2019 General $8,353 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Blake Peterson
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Blake Peterson were reported at $183,549. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Blake Peterson Orthopaedic Surgery median Middle half National median
2019 $8,353 $644 $140–$2,844 $163
2020 $39,124 $312 $75–$1,860 $114
2021 $26,267 $520 $117–$2,495 $132
2022 $38,561 $598 $128–$2,731 $149
2023 $52,234 $461 $128–$2,264 $160
2024 $33,665 $497 $134–$2,475 $164
2025 $183,549 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $367,789 467 payments
  2. Smith+Nephew, Inc. $10,291 14 payments
  3. Stryker Corporation $1,330 19 payments
  4. Globus Medical, Inc. $817 5 payments
  5. KCI USA, Inc $800 1 payment
  6. Medical Device Business Services, Inc. $114 1 payment
  7. Davol Inc. $80 3 payments
  8. Ferring Pharmaceuticals Inc. $78 5 payments
  9. MIMEDX Group, Inc. $74 2 payments
  10. Radius Health, Inc. $56 3 payments
  11. Other $323 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $176,938 55 payments
  2. Consulting Fee $161,335 78 payments
  3. Travel and Lodging $35,858 226 payments
  4. Food and Beverage $7,622 179 payments
Products named General payments · program years 2019–2025
  1. Avenir Hips $146,914 167 payments
  2. G7 Hips $119,871 50 payments
  3. Arcos $60,190 52 payments
  4. Avenir Hips $33,675 47 payments
  5. ROSA Hips $21,328 8 payments
  6. ROSA Knees $18,129 26 payments
  7. Avenir Hips $13,221 28 payments
  8. G7 Hips $13,070 9 payments
  9. G7 Hips $11,250 6 payments
  10. REAL INTELLIGENCE $9,528 11 payments
  11. Other $65,737 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,766

Median for Orthopedic Surgery: 203

Drug cost

$20,819

Median for Orthopedic Surgery: $1,433

Branded share of claims

41%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 386 $9,753
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 357 $4,453
Ondansetron Odt Ondansetron Brand 352 $4,301
Tramadol Hcl Generic 529 $1,414
Tranexamic Acid Generic 25 $350
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $124
Cephalexin Generic 14 $121
Cyclobenzaprine Hcl Generic 18 $103
Cefadroxil Generic 24 $90
Dexamethasone Generic 23 $66

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$469,828

Of which drugs: $649

Medicare patients

845

Average age 74

Services billed

7,831

503 women, 342 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 28%
Chronic kidney disease 24%
Atrial fibrillation 20%
Depression 19%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 35 5,220 $541
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 20 $108

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $4
$4 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

538 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record